Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: CA Cancer J Clin. 2017 Jul 6;67(5):411–431. doi: 10.3322/caac.21403

TABLE 3.

Metabolism and transporter effects of direct-acting antivirals

Direct-acting antiviral Metabolism Transporter effects
Sofosbuvir Hepatic; forms active nucleoside analog triphosphate GS461203 P-gp and BCRP substrate
Sofosbuvir-ledipasvira Slow oxidative metabolism via unknown mechanism P-gp and BCRP substrate
Inhibits P-gp, BCRP, OATP1B1, OATP1B3, and bile salt export pump
Sofosbuvir-velpatasvira Hepatic via CYP2B6, CYP2C8, and CYP3A4 P-gp and BCRP substrate
Inhibits P-gp, BCRP, OATP1B1, OATP1B3, and OATP2B1
Ritonavir-boosted paritaprevir-omibitasvir-dasabuvirb Ritonavir-boosted paritaprevir
Hepatic via CYP3A4 (primary) and CYP3A5
Ombitasvir
Hydrolysis
Dasabuvir
Hepatic- via CY2C8 (primary) and CYP2C8
Ritonavir-boosted paritaprevir
P-gp, BCRP, OATP1B1, and OATP1B3 substrate
Inhibits P-gp, BCRP, UGT1A1, OATP1B1, and OATP1B3
Ombitasvir
P-gp and BCRP substrate
Inhibits P-gp, BCRP, and UGT1A1
Dasabuvir
P-gp and BCRP substrate
Inhibits P-gp, BCRP, and UGT1A1
Grazoprevir-elbasvir Hepatic via CYP3A4 (partial) Grazoprevir
OATP1B1 and OATP1B3 substrate; transported by P-gp
Inhibits BCRP (intestinal level), and CYP3A(weak)
Elbasvir
Inhibits BCRP (intestinal level)
Daclatasvir Hepatic via CYP3A CYP3A4 and P-gp substrate
Inhibits BCRP, P-gp, OATP1B1, and OATP1B3 (moderate)
Simeprevir Hepatic via CYP3A (primary), CYP2C8, and CYP2C19 CYP3A4, P-gp, BCRP, OATP1B1, OATP1B3, and OATP2B1 substrate; transported by OATP1B1 and OATP1B3
Inhibits OATP1B1, OATP1B3, P-gp, BCRP, BSEP, CYP1A2 (mild), and CYP3A4 (mild)
Ribavirinc Hepatic and intracellular Inhibits CYP1A2 and IMDH

BCRP, breast cancer resistance protein; CYP, cytochrome P450 enzymatic system; IMDH, inosine monophosphate dehydrogenase; OATP, organic anion transporting polypeptide; P-gp, p-glycoprotein.

a

Metabolism and transporter effects do not include sofosbuvir; refer to sofosbuvir for information.

b

Ritonavir has no activity against HCV but is given as a low-dose CYP3A inhibitor to boost paritaprevir concentration.

c

Ribavirin is often used in combination with DAAs; therefore, it is included to provide a comprehensive overview.